ISOPTO ATROPINE Drug Patent Profile

Which patents cover Isopto Atropine, and when can generic versions of Isopto Atropine launch?

Isopto Atropine is a drug marketed by Alcon Labs Inc and is included in one NDA.

The generic ingredient in ISOPTO ATROPINE is atropine sulfate. There are twenty-three drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the atropine sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Isopto Atropine

A generic version of ISOPTO ATROPINE was approved as atropine sulfate by HOSPIRA on July 9^th, 2001.

Summary for ISOPTO ATROPINE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ISOPTO ATROPINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon Labs Inc	ISOPTO ATROPINE	atropine sulfate	SOLUTION/DROPS;OPHTHALMIC	208151-001	Dec 1, 2016	AT2	RX	Yes	Yes

ISOPTO ATROPINE: PATENT LANDSCAPE AND INVESTMENT FUNDAMENTALS

Last updated: February 18, 2026

This report analyzes the patent landscape and investment fundamentals for ISOPTO ATROPINE. The drug is an ophthalmic solution containing atropine sulfate. Primary indications include cycloplegia and mydriasis for diagnostic procedures and treatment of uveitis. Key patent expirations and market exclusivity periods are analyzed to assess future competitive entry and revenue potential.

What is ISOPTO ATROPINE's Composition and Mechanism of Action?

ISOPTO ATROPINE is a brand name for ophthalmic atropine sulfate. Atropine is a competitive antagonist of acetylcholine at muscarinic receptors. In the eye, this antagonism leads to paralysis of the ciliary muscle (cycloplegia) and dilation of the pupil (mydriasis). This effect is utilized in ophthalmology for several purposes. Diagnostic uses include facilitating fundus examinations and determining refractive error in children by temporarily paralyzing accommodation. Therapeutic uses include managing anterior uveitis by dilating the pupil to prevent posterior synechiae formation (adhesions between the iris and the lens) and reducing ciliary spasm, thereby alleviating pain. The typical concentration for ophthalmic use is 1% atropine sulfate. The formulation often includes viscosity-enhancing agents to prolong ocular contact time.

What is the Current Patent and Exclusivity Status of ISOPTO ATROPINE?

The active pharmaceutical ingredient (API), atropine sulfate, has been in public use and is not subject to new composition of matter patents. The primary market exclusivity for ISOPTO ATROPINE is derived from its brand status and formulation patents, which are nearing expiration or have already expired for the core product.

• US Patent Expirations: Original formulation patents for ISOPTO ATROPINE have long since expired. For example, patents related to improved delivery or formulation enhancement, if any were granted for specific ISOPTO ATROPINE formulations, would have expiration dates typically in the early to mid-2000s. Without specific patent numbers for the original ISOPTO ATROPINE brand formulation, general knowledge of pharmaceutical patent lifecycles indicates that foundational patents for established drugs like atropine ophthalmic solutions would have expired decades ago.
• European Patent Expirations: Similar to the US, fundamental patents protecting the use of atropine sulfate in ophthalmic solutions are expired. Any subsequent formulation improvements would have had their patent protection expire within the last 10-20 years.
• Data Exclusivity: For newer indications or advanced formulations, data exclusivity periods can provide market protection separate from patent protection. However, for ISOPTO ATROPINE, as an established and widely known ophthalmic agent, it is unlikely to benefit from recent data exclusivity grants.

The absence of strong, pending patent protection for the core ISOPTO ATROPINE product opens the door for generic competition. Manufacturers of generic atropine sulfate ophthalmic solutions can enter the market once primary patents and exclusivities expire, provided they meet regulatory approval standards.

What is the Competitive Landscape for Atropine Sulfate Ophthalmic Solutions?

The market for atropine sulfate ophthalmic solutions is characterized by the presence of both branded and generic products. Competition is driven by pricing, availability, and established physician trust.

• Branded Products: ISOPTO ATROPINE itself represents the branded product. Other branded formulations of atropine sulfate ophthalmic solution may exist, often differentiated by excipients, preservative systems, or specific marketed indications.
• Generic Competitors: Numerous generic manufacturers produce atropine sulfate ophthalmic solutions, particularly in the 1% concentration. These generics compete primarily on price. The availability of multiple generic options intensifies price pressure.
• Alternative Treatments: For cycloplegia and mydriasis, other agents like cyclopentolate hydrochloride and tropicamide are also used. These alternatives offer different onset and duration profiles and may be preferred for specific clinical situations. For uveitis, while atropine is a standard, other anti-inflammatory agents are used in conjunction or as primary therapy depending on the underlying cause.

The presence of established generics with lower price points represents a significant competitive challenge to branded ISOPTO ATROPINE.

What are the Market Size and Growth Projections for Ophthalmic Atropine Sulfate?

Estimating the precise market size for ISOPTO ATROPINE as a distinct product is challenging due to the prevalence of generic competition. Market data typically aggregates atropine sulfate ophthalmic solutions.

• Global Market Size: The global ophthalmic drugs market, which includes atropine sulfate solutions, is substantial. Reports indicate the global ophthalmic drug market was valued at approximately USD 25 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 5-7% through 2030 [1]. Atropine sulfate solutions represent a segment within this larger market, primarily for diagnostic and therapeutic ophthalmology.
• Growth Drivers: Growth in the atropine sulfate market is influenced by increasing prevalence of eye conditions requiring diagnostic imaging, rising incidence of uveitis, and an aging population. Demand for routine eye examinations, particularly in pediatric populations, contributes to the need for cycloplegics.
• Regional Variations: Market penetration and growth vary by region, influenced by healthcare infrastructure, reimbursement policies, and physician prescribing habits. Developed markets with higher healthcare spending and routine eye care access exhibit higher demand.

While specific growth figures for atropine sulfate ophthalmic solutions are not always segmented, the overall growth trend in ophthalmology suggests a stable to moderate growth trajectory for established products like atropine. However, the increasing commoditization due to generic availability can cap revenue growth for branded entities.

What is the Regulatory Pathway and Approval Status?

ISOPTO ATROPINE, as a branded ophthalmic solution, is approved by regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

• FDA Approval: Atropine sulfate ophthalmic solutions are approved by the FDA for indications such as ophthalmological examinations and treatment of uveitis. The approval pathway for such established drugs typically involved New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs) for generics.
• EMA Approval: Similarly, the EMA has approved atropine sulfate ophthalmic preparations.
• Generic Approvals: The ANDA pathway allows generic manufacturers to seek approval by demonstrating bioequivalence to the reference listed drug (RLD). This process significantly lowers the barrier to entry for generic competitors.
• Pharmacopeial Standards: The quality and purity of atropine sulfate ophthalmic solutions are governed by pharmacopeial standards, such as those set by the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP). Manufacturers must adhere to these standards for product quality and consistency.

The established regulatory framework and the existence of numerous generic approvals indicate a mature market with limited opportunities for significant regulatory innovation unless a novel formulation or delivery system is introduced and patented.

What are the Key Financial Considerations for Investment?

Investment in ISOPTO ATROPINE or its therapeutic class requires evaluating profitability against market dynamics.

• Revenue Streams: Revenue for the branded ISOPTO ATROPINE product is primarily driven by sales volume and pricing. Post-patent expiration, pricing power is severely diminished due to generic competition.
• Cost Structure: Manufacturing costs for atropine sulfate ophthalmic solutions are relatively low, as the API is an established chemical entity. Formulation and packaging costs are standard. Marketing and distribution expenses are significant for branded products but can be reduced for generics.
• Generic Erosion: The primary financial risk is the rapid erosion of market share and profitability upon the entry of generic competitors. This typically leads to steep price declines, often exceeding 80-90% within the first year of generic availability.
• Profitability of Generics: Generic manufacturers can achieve profitability through high-volume sales and low-cost production. The investment case for generics relies on efficient manufacturing and a robust distribution network.
• Company Strategy: A company solely reliant on ISOPTO ATROPINE revenue would face significant challenges due to generic competition. Diversification into newer, patent-protected drugs or a strategic shift towards generic manufacturing would be necessary for long-term viability.

Analysis of historical sales data for branded ISOPTO ATROPINE and comparable ophthalmic solutions would provide insights into the typical revenue trajectory post-generic entry.

What are the Future Opportunities and Threats?

The future for ISOPTO ATROPINE is largely defined by its status as a mature, off-patent product.

Opportunities

• Generic Market Dominance: For manufacturers with robust generic production capabilities, ISOPTO ATROPINE represents a steady revenue stream through high-volume generic sales.
• Emerging Markets: As healthcare infrastructure develops in emerging economies, the demand for essential ophthalmic medications like atropine sulfate is expected to increase, providing opportunities for both branded and generic players.
• Combination Therapies: While not directly related to ISOPTO ATROPINE itself, research into novel combination therapies for conditions like myopia management or complex uveitis could potentially utilize atropine sulfate as a component. However, this would require new patentable intellectual property for the combination.

Threats

• Intensifying Generic Competition: The market is already crowded with generic atropine sulfate solutions. Further price declines are likely as more manufacturers enter or expand their presence.
• Therapeutic Alternatives: The ongoing development of new diagnostic tools and alternative therapeutic agents for ophthalmic conditions could reduce the reliance on atropine sulfate.
• Reimbursement Pressures: Healthcare payers, including government programs and private insurers, are increasingly focused on cost containment. This can lead to lower reimbursement rates for off-patent drugs, impacting profitability.
• Supply Chain Disruptions: Like any pharmaceutical product, ISOPTO ATROPINE is subject to supply chain vulnerabilities, including API sourcing issues and manufacturing challenges.

Key Takeaways

• ISOPTO ATROPINE is an established ophthalmic solution based on atropine sulfate, a compound whose fundamental patents have expired.
• Market exclusivity for the branded product has largely lapsed, leading to a highly competitive generic market.
• The global ophthalmic drug market is growing, but the segment for atropine sulfate solutions is characterized by price-based competition.
• Regulatory approvals are well-established, with multiple generic versions available, facilitating market entry for competitors.
• Investment in branded ISOPTO ATROPINE presents significant risks due to generic erosion; profitability is more likely for generic manufacturers with efficient operations.
• Future opportunities lie in generic market penetration, especially in emerging economies, and potentially in novel combination therapies, though these require new intellectual property.

Frequently Asked Questions

What is the primary clinical use of ISOPTO ATROPINE?

ISOPTO ATROPINE is primarily used to induce cycloplegia (paralysis of the ciliary muscle) and mydriasis (pupil dilation) for ophthalmic diagnostic examinations and to manage inflammatory conditions like uveitis by preventing synechiae and reducing pain.

How does the expiration of patents affect ISOPTO ATROPINE's market position?

Patent expiration allows generic manufacturers to produce and sell bioequivalent versions of atropine sulfate ophthalmic solution. This leads to increased competition, significant price reductions, and a substantial decline in market share and revenue for the branded product.

What are the main competitors to ISOPTO ATROPINE?

The main competitors are generic manufacturers of atropine sulfate ophthalmic solutions. Additionally, other ophthalmic mydriatic and cycloplegic agents, such as cyclopentolate and tropicamide, serve as therapeutic alternatives for similar clinical indications.

What is the typical price trend for ISOPTO ATROPINE after generic entry?

Following the introduction of generic competitors, the price of branded ISOPTO ATROPINE typically declines sharply. Generic versions compete aggressively on price, leading to price erosion that can exceed 80% within the first year of market entry.

What is the outlook for investment in the atropine sulfate ophthalmic solution market?

Investment in the branded ISOPTO ATROPINE product carries high risk due to commoditization and price erosion. However, for companies focused on generic pharmaceutical manufacturing, the market offers opportunities for stable revenue through high-volume sales of cost-effective atropine sulfate ophthalmic solutions.

Citations

[1] Grand View Research. (2023). Ophthalmic Drugs Market Size, Share & Trends Analysis Report By Drug Class (Anti-allergy, Anti-glaucoma, Anti-infectives, Anti-inflammatories, Drugs for Age-Related Macular Degeneration, Others), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 – 2030.